NRXP — NRX Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $75.59m
- $82.91m
Annual income statement for NRX Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.555 | 116 | 44.3 | 27.8 | 20.6 |
| Operating Profit | -0.555 | -116 | -44.3 | -27.8 | -20.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.07 | -93.1 | -39.8 | -30.1 | -25.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.09 | -93.1 | -39.8 | -30.1 | -25.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.09 | -93.1 | -39.8 | -30.1 | -25.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.09 | -349 | -39.8 | -30.2 | -25.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.82 | -69.8 | -6.04 | -0.395 | -2.27 |